Association between serum values of C-reactive protein and cytokine production in whole blood of patients with Type 2 diabetes

Clinical Science

Volumn 113, Issue 1-2, 2007, Pages 103-108

  Castoldi, Giovanna ^a,b   Galimberti, Stefania ^b   Riva, Chiara ^b   Papagna, Ruggero ^b   Querci, Federico ^c   Casati, Marco ^a   Zerbini, Gianpaolo ^d   Caccianiga, Gianluigi ^b   Ferrarese, Carlo ^b   Baldoni, Marco ^b   Valsecchi, Maria Grazia ^b   Stella, Andrea ^a,b  

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c Ospedale di Alzano Lombardo   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

C reactive protein (CRP); Cytokine; Inflammation; Insulin resistance; Interleukin; Lipopolysaccharide; Type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CYTOKINE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BODY MASS; CYTOKINE PRODUCTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STIMULUS RESPONSE; UNIVARIATE ANALYSIS;

AGED; C-REACTIVE PROTEIN; CYTOKINES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LINEAR MODELS; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447498697     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20060338     Document Type: Article

References (38)

1. Grundy, S. M., Benjamin, I. J., Burke, G. L. et al. (1999) Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100, 1134-1146
2. Reiss, A. B. and Glass, A. D. (2006) Atherosclerosis: immune and inflammatory aspects. J. Invest. Med. 54, 123-131
3. Gough, P. J., Gomez, I. G., Wille, P. T. and Raines, E. W. (2006) Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J. Clin. Invest. 116, 59-69
4. Engstrom, G., Hedblad, B., Janzon, L. and Lindgarde, F. (2006) Fatality of acute coronary events in relation to hypertension and low-grade inflammation: a population-based cohort study. J. Human Hypertens. 20, 581-586
5. Pirro, M., Schillaci, G., Savarese, G. et al. (2004) Low-grade systemic inflammation impairs arterial stiffness in newly diagnosed hypercholesterolaemia. Eur. J. Clin. Invest. 34, 335-341
6. Basu, S., Larsson, A., Vessby, J., Vessby, B. and Berne, C. (2005) Type 1 diabetes is associated with increased cyclooxygenase- and cytokine-mediated inflammation. Diabetes Care 28, 1371-1375
7. Pearson, T. A., Mensah, G. A., Alexander R. W. et al. (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499-511
8. Haverkate, F., Thompson, S. G., Pyke, S. D. M., Gallimore, J. R. and Pepys, M. B. (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349, 462-466
9. Liuzzo, G., Biasucci, L. M., Gallimore, J. R. et al. (1994) The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N. Engl. J. Med. 331, 417-424
10. Libby, P. and Ridker, P. M. (2004) Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am. J. Med. 116 (Suppl. 6), 9-16
11. Wilson, P. W. F., Nam, B-H., Pencina, M. et al. (2005) C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch. Intern. Med. 165, 2473-2478
12. Sattar, N., Murray, H. M., McConnachie, A. et al. (2007) C-reactive protein and prediction of coronary heart disease and global vascular events in the prospective study of pravastatin in the elderly at risk (PROSPER). Circulation 115, 981-989
13. Danesh, J., Wheeler, J. G., Hirschfield, G. M. et al. (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350, 1387-1397
14. Sattar, N. and Lowe, G. D. (2006) High sensitivity C-reactive protein and cardiovascular disease: an association built on unstable foundation? Ann. Clin. Biochem. 43, 252-256.
15. Pfutzner, A. and Forst, T. (2006) High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol. Ther. 8, 28-36
16. Freeman, D. J., Norrie, J., Caslake, M. J. et al. (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51, 1596-1600
17. Duncan, B. B., Schmidt, M. I., Pankow, J. S. et al. (2003) Low-grade systemic inflammation and the development of type 2 diabetes. The Atherosclerosis Risk in Communities Study. Diabetes 52, 1799-1805
18. Verma, S., Li, S. H., Badiwala, M. V. et al. (2002) Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105, 1890-1896
19. Pasceri, V., Chang, J., Willerson, J. T. and Yeh, E. T. H. (2001) Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103, 2531-2534
20. Devaraj, S., Kumaresan, P. R. and Jialal, I. (2004) Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J. Mol. Cell. Cardiol. 36, 405-410
21. Pepys, M. B., Hawkins, P. N., Kahan, M. C. et al. (2005) Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ. Res. 97, 97-103
22. Liu, C., Wang, S., Deb, A. et al. (2005) Proapoptotic, antimigratory, antiproliferative, and antiangiogenic effects of commercial C-reactive protein on various human endothelial cell types in vitro: implications of contaminating presence of sodium azide in commercial preparation. Circ. Res. 97, 135-143
23. Swafford, A. N., Bratz, I. N., Knudson, J. D. et al. (2005) C-reactive protein does not relax vascular smooth muscle: effects mediated by sodium azide in commercially available preparations. Am. J. Physiol. Heart Circ. Physiol. 288, H1786-H1795
24. Van den Berg, C. W., Taylor, K. E. and Lang, D. (2004) C-reactive protein-induced in vitro vasorelaxation is an artefact caused by the presence of sodium azide in commercial preparations. Arterioscler. Thromb. Vasc. Biol. 24, 168-171
25. Singh, U., Devaraj, S. and Jialal, I. (2005) C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells. Evidence that C-reactive protein is a procoagulant. Arterioscler. Thromb. Vasc. Biol. 25, 2216-2221
26. Devaraj, S., O'Keefe, G. and Jialal, I. (2005) Defining the proinflammatory phenotype using high sensitive C-reactive protein levels as the biomarker. J. Clin. Endocrinol. Metab. 90, 4549-4554
27. Bour, A. M. J. J., Westendorp, R. G. J., Laterveer, J. C. et al. (2000) Interaction of indomethacin with cytokine production in whole blood. Potential mechanism for brain-protective effect. Exp. Gerontol. 35, 1017-1024
28. Remarque, E. J., Bollen, E. L. E. M., Weverling-Rijnsburger, A. W. E. et al. (2001) Patients with Alzheimer's disease display a pro-inflammatory phenotype. Exp. Gerontol. 36, 171-176
29. Sala, G., Galimberti, G., Canevari, C. et al. (2003) Peripheral cytokine release in Alzheimer patients: correlation with disease severity. Neurobiol. Aging 24, 909-914
30. American Diabetes Association (2005) Standards of medical care in diabetes. Diabetes Care 28 (Suppl. 1), S4-S36
31. Dauphinee, S. M. and Karsan, A. (2006) Lipopolysaccharide signaling in endothelial cells. Lab. Invest. 86, 9-22
32. Fliser, D., Buchholz, K., Haller, H. and the European Trial on Olmesartan and Pravastatin in Inflammation Atherosclerosis (EUTOPIA) Investigators (2004) Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110, 1103-1107
33. Devaraj, S., Chan, E. and Jialal, I. (2006) Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J. Clin. Endocrinol. Metab. 91, 4489-4496
34. Zhong, Y., Li, S. H., Liu, S. M. et al. (2006) C-reactive protein upregulates receptor for advanced glycation end products expression in human endothelial cells. Hypertension 48, 504-511
35. Gill, R., Kemp, J. A., Sabin, C. and Pepys, M. B. (2004) Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. J. Cereb. Blood Flow Metab. 24, 1214-1218
36. Griselli, M., Herbert, J., Hutchinson, W. L. et al. (1999) C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J. Exp. Med. 190, 1733-1740
37. Pepys, M. B., Hirschfield, G. M., Tennent, G. A. et al. (2006) Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 440, 1217-1221
38. Ridker, P. M., Rifai, N., Rose, L. et al. (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347, 1557-1565